Table 4.

Clinical responses in efficacy-evaluable patients, phase II

Category, n (%)Follicular lymphoma (n = 14)Mantle cell lymphoma (n = 11)Total (N = 25)
ORR9 (64.3)3 (27.3)12 (48)
95% CI35.1–87.26.02–61.027.8–68.7
 CR1 (7.1)a01 (4)
 PR8 (57.1)3 (27.3)11 (44)
SD3 (21.4)4 (36.4)7 (28)
PD2 (14.3)4 (36.4)6 (24)
Median time to progression, days (range)625 (36–679+)120 (4–349+)625 (4–679+)
  • aCR was confirmed by positron emission tomography.